Radiation Oncology Group
EORTC 22863 – Phase III randomized clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy plus LHRH analogue.
Jointly with the EORTC Genito-Urinary Cancers Group
EORTC found that combining androgen suppression (during and after) external irradiation improves disease-free and overall survival in patients with locally advanced prostate cancer. This combined treatment approach was the first to show a major improvement in overall survival of patients, making it a gold standard of treatment.